REG - OptiBiotix Health - Market launch for LPLDL® capsules in Germany <Origin Href="QuoteRef">OPTIO.L</Origin>

OptiBiotix HealthAnnouncement

26/07/2017 07:00

RNS Number : 0645M
OptiBiotix Health PLC
26 July 2017
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Market launch forLPLDL capsulesin Germany
OptiBiotixHealthplc(AIM: OPTI),alifesciencesbusinessdevelopingcompoundstotackleobesity, high cholesterol,diabetes and skin care,announces that HLH BioPharma Vertriebs GmbH ("HLH") have achieved product registration of LPLDL capsules at IFA GmbH and "Bundesamt fr Lebensmittelsicherheit und Verbraucherschutz (BVL)" and commenced commercial sales to pharmacies in Germany on 24 July 2017.
This announcement follows on from the three year supply agreement with HLH BioPharma Vertriebs GmbH ("HLH") announced on 15 June 2017. HLH will market capsules containing LPLDL under the brand name Lactobact LDL-Control and promote them directly to the pharmacy market in Germany, as well as to consumers on their online platform.Sales revenuesare difficult to estimate in this new and developing market but arelikely to be in the low to mid six figure in the near term growing as HLH builds market presence.
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to see the first sales of ourLPLDL strain in products available to consumers in Germany. We hope this will be the first of many product launches of multiple formulations and presentations of LPLDL as the active component in a wide range of pharmaceutical and consumer products around the world. HLH have an international reputation for providing high quality and scientifically validated products and areone of Europe's leading suppliers of probiotics to the pharmacy market. Establishing early sales ofLPLDL to pharmacies with HLHhelps substantiate the credibility in the science behindLPLDL to build the brand and acceptance in the larger consumer healthcare markets."
For further information, please contact:
OptiBiotix Health plc
www.optibiotix.com
Stephen O'Hara, Chief Executive
Contact via Walbrook below


Cairn Financial Advisers LLP (NOMAD)
Tel: 020 7213 0880
Liam Murray / Jo Turner

finnCap (Broker)
Tel: 020 7220 0500
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)

Tony Quirke / Abigail Wayne (Corporate Broking)



Walbrook PR Ltd
Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy
Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen and OptiBiotic platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases. 

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCUVAVRBVABUAR